Di Bartolo, Paolo
Nicolucci, Antonio
Cherubini, Valentino
Iafusco, Diario
Scardapane, Marco
Rossi, Maria Chiara
Clinical trials referenced in this document:
Documents that mention this clinical trial
Young patients with type 1 diabetes poorly controlled and poorly compliant with self-monitoring of blood glucose: can technology help? Results of the i-NewTrend randomized clinical trial
https://doi.org/10.1007/s00592-017-0963-4
Article History
Received: 7 July 2016
Accepted: 5 January 2017
First Online: 30 January 2017
Compliance with ethical standards
:
: Paolo Di Bartolo has been member of Advisory Panels of Novo Nordisk Inc., Eli Lilly and Company, Abbott, Novartis Corporation; he received Speaker’s Bureau from Eli Lilly and Company, Novo Nordisk Inc., Merck Sharp & Dohme, Boehringer Ingelheim Pharmaceuticals, Inc., Medtronic, Inc.,Ypsomed, Menarini Group, Abbott, Novartis Corporation, Roche Diagnostics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Sanofi Pasteur SA. Maria Chiara Rossi has been member of an Advisory Panel of Novo Nordisk. Valentino Cherubini and Marco Scardapane have no conflict of interests. Dario Iafusco has been member of Advisory Panels of Eli Lilly and Company, Abbott and received Speaker’s Bureau from Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Medtronic, Inc., Roche Diagnostics, Sanofi Pasteur SA. Antonio Nicolucci received Research Support from Sanofi Pasteur SA, Novo Nordisk Inc., Merck Sharp & Dohme, Bristol‐Myers Squibb Company, ForaCare, Artsana, Sanofi, Novo Nordisk, Dexcom.
: The study was conducted following accepted principles of ethical and professional conduct.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).
: Informed consent was obtained from all patients for being included in the study.